



**COMPANY ANNOUNCEMENT  
19 November 2010**

**INTERNAL BOARD CHANGES**

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience drug development company, today announces the following changes within the Board.

Mr Michael Robson (currently Non Executive Director of NDL) has accepted the role as NDL chairman effective immediately.

Mr Robson has held a number of senior management positions both in the Western Australian government and in private industry since 2001. Mr Robson is also currently the Non-Executive Chairman and a director of Datamotion Asia Pacific Ltd (ASX: DMN). He is a specialist compliance and risk management consultant to the stockbroking and financial planning industries. His senior roles have included responsibility for corporate governance, corporate finance, investor relations, regulatory compliance, risk management, training, policy development and implementation and strategic planning.

Michael Robson – Non Executive Chairman
T: +61 (0)401 002 997
E: m.robson@satusworldwide.com

**-ENDS-**

**About NeuroDiscovery**

NeuroDiscovery Ltd is an ASX listed speciality neuroscience drug development company (ASX Code NDL).